MorphoSys Announces Clinical Milestone in Blood Disorders Program
News Jul 25, 2015
MorphoSys AG has announced that it has received a milestone payment from Novartis in connection with the initiation of a Phase 1 clinical trial of a HuCAL antibody in the field of blood disorders.
This becomes the eleventh therapeutic antibody made using MorphoSys's technologies that Novartis is evaluating in clinical trials. The associated milestone payment was booked in Q2 2015.
"With eleven therapeutic antibody programs in clinical development to date, our alliance with Novartis has resulted in a substantial drug candidate portfolio," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today's news represents the second clinical milestone with our partners during the course of this year."
MorphoSys's collaboration with Novartis has resulted in eleven clinical programs to date, six of which are in Phase 1 development, with another four programs in Phase 2 and one in Phase 3.
In total, MorphoSys's proprietary and partnered clinical pipeline currently comprises 24 unique antibody molecules, which are being evaluated in more than 50 clinical trials.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Scientists Cloak Anti-Cancer Drugs in Particles to Target and Destroy Tumor CellsNews
Scientists now report results showing that, by cloaking anti-cancer drugs in a specially designed particle, they could target and destroy tumor cells deep inside a malignant mass in vitro.